Biotech Developments

June 22, 2017

It might sound like something straight out of science fiction, but the race is on around the globe to find the secret to extending human life. It’s not actually as far-fetched as it might seem. After all, if you imagine that the majority of us alive today will eventually succumb to one disease or another, simply being able to find a cure or even partial cure to a common killer is enough to meet the criteria.

Spotlight

Qu Biologics In

Qu Biologics is a Vancouver-based, private, clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel proprietary immunotherapy platform.

OTHER VIDEOS

What is Genomic Medicine?

video | June 16, 2022

Our DNA contains 3 billion letters of code: our genome. Almost 99.8% is the same for everyone, but in the remaining 0.2% there are differences that can sometimes be harmful. With genomic medicine we can have our DNA analysed to look for these differences to inform and personalise our healthcare. Genomics England’s vision is to support the NHS to make genomic medicine available to every patient, whilst enabling researchers to improve our understanding of diseases....

Watch Now

Peptides From Phage Display Library Modulate Gene Expression In Mesenchymal Cells

video | June 8, 2022

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects - a 2 minute Preview of the Experimental Protocol Gary Balian, Gina Beck, Vedavathi Madhu, Robert Sikes, Quanjun Cui, Haixiang Liang, Joshua Bush University of Virginia, Orthopaedics Research; University of Delaware, Biological Sciences; University of Virginia, Orthopaedic Surgery; A phage display library was used to identify peptide sequences that target bone. The objective was to investigate the effect of these peptides on mesenchymal cell differentiation and to determine their effect on bone regeneration....

Watch Now

Would a society based on genetics be… good?

video | June 15, 2022

Eugenics is the practice of using "planned breeding" for "racial improvement." Because this idea is repulsive, the predominant response has been "genome blindness” — that is, avoiding any study or discussion of genetic differences between people. But according to geneticist Paige Harden, this is the wrong solution. Instead, we should identify genetic differences between people — including those that might affect social outcomes — so that we can help provide people with the resources they need to be successful....

Watch Now

mRNA Therapy for Fragile X Syndrome

video | June 2, 2022

Dr. Kathryn Whitehead, Associate Professor at Carnegie Mellon University, helped develop the revolutionary science behind the COVID-19 vaccines. With a 2 year $100,000 grant from FRAXA, her team will now adapt mRNA technology to deliver the missing Fragile X protein, to treat people who have Fragile X syndrome....

Watch Now

Spotlight

Qu Biologics In

Qu Biologics is a Vancouver-based, private, clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel proprietary immunotherapy platform.

Events